We examined the relative contribution of endothelial and vascular smooth muscle-derived prostaglandins and endothelium-derived relaxing factor in modulating both the large coronary artery and resistance vessel responses to thromboxane in vivo. Vascular responses to the thromboxane analogue U46619 were measured in four separate experimental protocols: 1) The vascular responses were measured in the presence and absence of intact endothelium to examine the role of endothelium-derived vasodilators. 2) Responses were measured in the presence of intact endothelium before and after inhibition of cyclooxygenase with indomethacin to examine the role of endothelial and vascular smooth muscle-derived prostaglandins. 3) Responses were measured after endothelial removal before and after indomethacin to examine the role of vascular smooth muscle-derived prostaglandins. 4) Responses were measured after indomethacin and before and after removal of endothelium to examine the role of endotheliumderived relaxing factor. In anesthetized dogs (n =41) that underwent constant pressure perfusion of the left anterior descending coronary artery (LAD), LAD diameter was measured with sonomicrometer crystals, and coronary flow was measured with an electromagnetic flow probe. Intracoronary infusion of U46619 (0.01-1.0 ,ug/min) produced a dose-dependent constriction of LAD. Constriction of the LAD was augmented after endothelial removal, after indomethacin treatment in both the presence and absence of endothelium, and after removal of the endothelium in the presence of indomethacin. Inhibition of prostaglandin synthesis had the greatest effect of augmenting constriction of LAD to thromboxane. Coronary flow was decreased by U46619 only in the presence of indomethacin. We conclude that both endothelial and vascular smooth muscle-derived prostaglandins and endothelium-derived relaxing factor can modulate the coronary response to U46619 in vivo; however, prostaglandins appear to play a more prominent role. (Circulation Research 1990;66:1729-1737 Since the discovery that the endothelium is a major source of vasodilator substance(s) that is distinct from the prostaglandin pathway,' a great deal of study has focused on the role of endothelium-derived relaxing factor (EDRF) in modulating vascular responses to both humoral and physicochemical stimuli.23 Although the release of EDRF has been shown to modulate vascular responses in vivo,3-5 the importance of vasodilator prostaglandins in modulating vascular responses should also be assessed.
Since the discovery that the endothelium is a major source of vasodilator substance(s) that is distinct from the prostaglandin pathway,' a great deal of study has focused on the role of endothelium-derived relaxing factor (EDRF) in modulating vascular responses to both humoral and physicochemical stimuli. 23 Although the release of EDRF has been shown to modulate vascular responses in vivo, 3- Perturbation of the balance of vascular constrictor and dilator influences is thought to be important in the initiation of coronary vasospasm. The opposing effects of platelet-derived thromboxane and vascular prostaglandins may play a role in maintaining coronary arteiy tone in the normal vessel.6'7 Inhibition of prostaglandin synthesis with indomethacin constricts intact canine coronary arteries both in vitro and in vivo,8 denuded coronary arteries in vivo,9 and the coronary circulation of patients with coronary vascular disease. 10 The vasoconstriction to indomethacin is due to inhibition of prostaglandin synthesis and a decrease in the level of vasodilating prostaglandins.8 Inhibition of prostaglandin production also results in augmented constriction to a variety of humoral substances.1"12 Aspirin pretreatment enhanced vaso-Both endothelium and vascular smooth muscle have been shown to be sources of vasodilator prostaglandins such as prostacyclin.14,15 Endothelium can produce vasodilators, such as EDRF, independent of their ability to release prostaglandins. It is valuable to determine which of the vasodilator substances, EDRF or prostaglandins, is the major modulating factor(s) in the response of the coronary artery to vasoconstrictors such as thromboxane.
In the present study, we tested the hypothesis that the vascular wall of the coronary circulation modulates the vasoconstrictor effects of thromboxane in vivo through release of both EDRF and prostaglandins. We determined the source of these vasodilator substances, either endothelium or vascular smooth muscle, by examining large coronary artery and flow responses to the thromboxane analogue U46619 (9,11-dideoxy-9a,1la-epoxymethanoprostaglandin F2a, The Upjohn Company, Kalamazoo, Michigan) in the presence and absence of intact endothelium and before and after inhibition of the cyclooxygenase pathway with indomethacin. By measuring the response of coronary arteries to U46619 before and after indomethacin and before and after removal of endothelium, we assessed the relative importance of EDRF and all vascular (both endothelial and vascular smooth muscle) prostaglandins.
Materials and Methods Animal Preparation
Adult mongrel dogs of either sex (22-28 kg) were anesthetized with sodium pentothal (25 mg/kg i.v.) followed by a-chloralose (100 mg/kg i.v.). The animals were intubated and ventilated with a mechanical respirator with an end-expiratory pressure of 3-5 cm water. Arterial blood gases were monitored, and the rate and volume of respiration were adjusted to maintain gases in the physiological range (pH 7.35-7.45, P02 80-130, Pco2 35-45 mm Hg).
A left thoracotomy in the fifth intercostal space was used to approach the heart, which was suspended in a pericardial cradle. Heart block was produced by injecting 37% formalin into the atrioventricular node. Biventricular epicardial pacer leads were placed, and the heart was paced above the intrinsic rate to maintain constant heart rate throughout the experiment.
One to 2 cm of proximal left anterior descending coronary artery (LAD) was dissected free of surrounding tissue to be used for sonomicrometer crystal placement. Another segment of LAD proximal to the crystal site was dissected free and cannulated for LAD perfusion. Coronary perfusion pressure was monitored through a side port on the cannula. Aortic blood pressure was measured with a catheter placed in the femoral artery and passed to the aortic arch. A femoral vein was cannulated and used for intravenous fluid and drug administration.
Coronary Diameter Measurement
Piezoelectric crystals were used to measure instantaneous coronary diameter with a technique described by Drews et al. 16 Two 20-MHz crystals were mounted on opposing sides of a steel clip. One crystal was embedded in a polyurethane cup that conformed to the artery and ensured constant position of the sonic beam in relation to the artery. The other crystal rested on the adventitial surface on the opposite side of the vessel. Appropriate diameter measurement was verified by noting in-phase diameter and perfusion pressure signals. Stability and resolution of this technique has been previously reported. 16 
Coronary Perfusion
After administration of heparin (500 units/kg followed by 250 units/hr), the LAD was perfused with blood from a pressurized arterial reservoir maintained at 370 C, and the pressure was maintained at 80 mm Hg. The blood leaving the reservoir passed through an in-line electromagnetic flow probe, and coronary flow was measured with a flowmeter. The flowmeter was calibrated with the dog's blood at the end of each experiment, and mechanical zero was checked repeatedly throughout the experiment.
Assessment of Endothelial Integrity
The presence or absence of endothelium was assessed in two ways. Endothelium-dependent dilator responses were measured to an intracoronary infusion of acetylcholine (40 ,g/min) after the coronary diameter and flow had reached steady-state values to the highest dose of intracoronary U46619.
Visual assessment of endothelium was done with scanning electron microscopy after completion of any experiment involving endothelial denudation. Denudation was felt to be adequate if dilation to acetylcholine was reduced to 25% of predenuded values and if the artery was devoid of endothelium under electron microscopy. Experiments that did not meet these criteria were excluded from analysis.
Experimental Protocol
This investigation is comprised of four separate experimental groups. Each group involves measurement of coronary responses to thromboxane analogue U46619 before and after intervention.
Effect ofendothelium on responses to U46619. In the first group of dogs (n=13), the effects of endothelial factors in modulating coronary artery responses to thromboxane were assessed. The thromboxane analogue U46619 was dissolved in 0.9% saline and infused at rates of 0.01, 0.1 and 1.0 ,ug/min i.c. until flow and coronary diameter were stable, usually within 5-10 minutes. Flow rate of infusion never exceeded 1 ml/min. Endothelial denudation was performed by introducing a 3F balloon-tipped Fogarty embolectomy catheter (Edwards Laboratories, Santa Ana, California) through a side port in the external perfusion system. The catheter was advanced 1 cm distal to the crystal site, inflated to reduce coronary flow to zero, and then withdrawn to the cannula tip. Total ischemic time was less than 30 seconds. Fortyfive minutes later, when coronary diameter and blood flow had returned to baseline, the dose-response curve to U46619 was repeated.
To assess any time-dependent and hemodynamic effects on coronary diameter responses to thromboxane, repeated dose-response curves were carried out in a separate series of 10 dogs without endothelial denudation.
Effect of endothelial and vascular smooth muscle prostaglandins. In the second group of dogs (n=10), the effect of vascular prostaglandins both from endothelium and vascular smooth muscle in modulating coronary artery responses to thromboxane was assessed by measuring coronary diameter and flow during a U46619 infusion (0.01, 0.1, 1.0 ,ug/min) before and after cyclooxygenase inhibition. Cyclooxygenase inhibition was accomplished by indomethacin treatment. Crystalline indomethacin was dissolved in 0.9% saline at a concentration of 1.0 mg/ml with sodium carbonate added 1:3 by weight. Indomethacin (5 mg/kg) was infused intravenously, and 45 minutes was allowed for cyclooxygenase inhibition. Inhibition of cyclooxygenase was verified by loss of flow responses to intracoronary infusion of arachidonic acid (400 ,ug/min) in three dogs: the percent change in flow was 63±20% before cyclooxygenase inhibition and 4+9% after cyclooxygenase inhibition.
Effect of vascular smooth muscle prostaglandins. In the third group of dogs (n = 9), the LAD was denuded of endothelium to assess the role of prostaglandins from vascular smooth muscle alone in the response of large coronary arteries to thromboxane. Forty-five minutes later, coronary diameter and flow responses to infusion of U46619 were measured before and after indomethacin treatment (5 mg/kg i.v.). Infusion of U46619 was adjusted for changes in coronary blood flow to keep the concentration similar before and after indomethacin treatment. Control experiments for determining possible hemodynamic and temporal effects on observed differences in denuded coronary artery responses to U46619 consisted of repeated dose-response curves to U46619 after endothelial denudation before and after infusion of saline.
Effect ofEDRF. In the fourth group of dogs (n=9), the effect of nonprostaglandin EDRF in modulating large coronary artery responses to thromboxane was measured. The dogs were pretreated with indomethacin (5 mg/kg i.v.), and 45 minutes was allowed for stabilization before any other drug infusion. Responses to thromboxane were then measured before and after endothelial removal.
Control experiments consisted of repeated doseresponse curves in six dogs to infusion of U46619 in arteries pretreated with indomethacin but without endothelial denudation between the two infusions.
Statistical Analysis
All data are represented as mean+SEM. Data from dose-response curves to thromboxane analogue U46619 before (dose-response 1) and after (doseresponse 2) an intervention were compared using a two-way analysis of variance, followed by a leastsquares mean analysis. The significance level was adjusted for multiple comparisons by the Bonferroni method.17 Coronary diameters and flows before and after an intervention alone (not in response to U46619) and acetylcholine responses were compared with a two-tailed t test.
Criteria for an Acceptable Experiment Animals were excluded from the study if 1) mean arterial pressure was less than 60 mm Hg, 2) peak reactive hyperemic response was less than 2: 1, or 3) blood gases could not be maintained in the physiological range as outlined in the "Animal Preparation" section above.
Results

Effect of Endothelial Removal on Responses to Thromboxane
Thromboxane analogue U46619 caused a dosedependent constriction of the proximal LAD artery (Figure 1 ). Coronary blood flow was decreased from control only at the highest infusion of thromboxane (Table 1) (Figure 2 ). Although coronary blood flow was not affected before indomethacin treatment, there was a marked diminution of flow after indomethacin ( Figure 3 , Table 2 ). Because of the decreases in coronary blood flow in response to thromboxane after indomethacin, drug concentrations of thromboxane and flow-dependent factors could have influenced the observed potentiation of coronary artery constriction. To assess possible effects of increased concentrations of thromboxane on this potentiation, in four dogs (included in the original group) infusion rates were decreased in the postindomethacin dose-response curve to achieve the same final concentration of thromboxane. In each acin, 2.25+0.13 mm;p<0.05). There was potentiation of constriction to thromboxane at 1.0 ,ug/min infusion rate after indomethacin (Figure 4) . Coronary blood flow responses were similar to those after indomethacin in the presence of intact endothelium. There was a decrease in coronary blood flow at control and at each infusion rate of thromboxane after indomethacin (Table 3) . Aortic blood pressures tended to be higher with postindomethacin infusion of thromboxane, but not significantly higher. Repeated dose-response curves to U46619 after endothelial denudation constricted the large artery similarly. The maximal change in diameter from control was as follows: for dose-response 1 (at 1.0 ,ug/min U46619), -136±35 ,um; for dose-response 2 (at 1.0 ,gg/min U46619), -172+52 gm. Coronary blood flows were also similar at each infusion rate of thromboxane, reflecting lack of indomethacin effect, and there was no significant difference in aortic pressure between the two dose-response curves.
Effects of Denudation on Coronary Artery Responses to Thromboxane Pretreated With Indomethacin
In nine dogs, the effects of denudation of endothelium on coronary artery response to thromboxane Thromboxane (Table 4) .
Denudation potentiated the constriction of large coronary arteries to U46619 pretreated with indomethacin. The difference was significant at the highest infusion rate ( Figure 5 ).
Repeated dose-response curves to U46619 were carried out in six dogs pretreated with indomethacin, to assess temporal and flow-dependent effects on coronary diameters. In contrast to the U46619-infused group, there were lower coronary blood flows in the second dose-response curve in the control group, significantly lower at the control and 1.0 gg/min U46619 infusion rates (coronary blood flow for dose-response 1: control, 43±7 ml/min; 1.0 jig/ min U46619, 20+6 ml/min; coronary blood flow for dose-response 2: control, 27±4 ml/min; 1.0 ,ug/min U46619,12±4 ml/min). Nevertheless, coronary diameter responses were similar between the two doseresponse curves in the control group, suggesting that the potentiation of vasoconstriction in the U46619-infused group was secondary to denudation. The maximal change in diameter from control was as follows: for dose-response 1 (at 1.0 ,um/min U46619), -235±65 ,um; for dose-response 2 (at 1.0 ,ug/min U46619), -262±90 gum.
Discussion
The primary finding of this study is that the coronary vascular wall produces factors that modulate the vasoconstriction produced by exogenously administered thromboxane in the intact circulation. In the large coronary artery these factors are derived from both the endothelium and smooth muscle. The factors include, but are not limited to, endothelial nonprostaglandins and smooth muscle prostaglandins. The contribution of endothelial prostaglandins 
Methodological Considerations
There are several aspects of the experimental design and method that could influence the interpretation of the results. Thromboxane is an unstable molecule; thus, the study of its effects is difficult. In this study, the thromboxane analogue U46619 was used. U46619 mimics natural thromboxane in its vasoconstrictor and platelet-activating properties.18 '19 It is possible that there are unknown differences between the analogue and the native compound that could alter the conclusions drawn from this study.
Indomethacin was used with the intent to inhibit cyclooxygenase in the vascular wall to assess the modulation of prostaglandins in thromboxane vasoconstriction. Unfortunately, indomethacin probably inhibited cyclooxygenase systemically, including that in platelets. This in turn could have reduced potential thromboxane synthesis in platelets stimulated by external U46619 infusion and may have underestimated the extent of vasoconstriction observed compared with that if vascular wall cyclooxygenase could have been inhibited selectively. The acin or aspirin treatment in denuded arteries but was enhanced in intact arteries, suggesting that the endothelial factor responsible for this effect was a prostaglandin. Potentiation of constrictor effects by indomethacin has also been demonstrated for other agents, including noradrenalin and potassium. 29 By blocking the cyclooxygenase pathway, it is possible that arachidonic acid may be shunted to the lipoxygenase pathway, which could contribute to the enhanced vasoconstriction observed. An increase in leukotriene production and a decrease in prostaglandins were measured after angioplasty in carotid arteries of dogs.30 It is unlikely that leukotrienes play a prominent role in the augmentation of constriction to thromboxane in the presence of indomethacin since leukotrienes are known to be potent constrictors of coronary vascular resistance vessels and not large coronary vessels.31 A likely explanation for our findings is that prostaglandin production is stimulated by thromboxane and that removal of these prostaglandins enhances the vasoconstriction to thromboxane. This is in contrast to the observation that indomethacin treatment does not modify the relaxation response to serotonin in endothelial intact arteries, suggesting that serotonin does not stimulate the release of prostaglandins from the arterial wall at least in in vitro preparations.32
Vascular Smooth Muscle Prostaglandins
The endothelium is a known source of prostaglandin production,14,15 although smooth muscle cells have been shown to produce equivalent amounts of prostacyclin as endothelial cells in culture. 33 It has also been demonstrated that denuded rat aorta produces enhanced amounts of prostacyclin, compared with intact aorta, in response to thromboxane analogue U46619 and other vasoconstrictors. 34 The role of smooth muscle prostaglandin production in modulating the constriction to thromboxane was investigated in the third group of dogs. When endothelial factors were removed (prostaglandin and nonprostaglandin) by prior mechanical denudation, indomethacin treatment still markedly potentiated constrictor responses to thromboxane. This suggests that smooth muscle is a large source of prostaglandin production in denuded arteries in limiting the vasoconstriction to thromboxane. Similar enhancement of constriction was observed to serotonin after indomethacin treatment in in situ preparations of denuded canine coronary arteries. 35 Potentiation of constriction to noradrenalin after indomethacin treatment was also observed in denuded canine thoracic aorta segments, which correlated with reduction of prostaglandin production.29 EDRF(s) In the fourth group of dogs, the role of EDRF(s) in modulating the constriction to thromboxane was evaluated. Although the potentiation of constriction after denudation in arteries pretreated with indomethacin was significant at the 1.0 ,ug/min U46619 
